Barrera-Ocampo Alvaro, Lopera Francisco
Departamento de Ciencias Farmacéuticas , Grupo de Investigación Natura, Facultad de Ciencias Naturales , Universidad Icesi , Cali, Colombia.
Grupo de Neurociencias de Antioquia , Escuela de Medicina, Universidad de Antioquia, Medellin, Colombia.
Colomb Med (Cali). 2016 Dec 30;47(4):203-212.
Alzheimer disease (AD) is the most prevalent form of dementia of adult-onset, characterized by progressive impairment in cognition and memory. There is no cure for the disease and the current treatments are only symptomatic. Drug discovery is an expensive and time-consuming process; in the last decade no new drugs have been found for AD despite the efforts of the scientific community and pharmaceutical companies. The Aβ immunotherapy is one of the most promising approaches to modify the course of AD. This therapeutic strategy uses synthetic peptides or monoclonal antibodies (mAb) to decrease the Aβ load in the brain and slow the progression of the disease. Therefore, this article will discuss the main aspects of AD neuropathogenesis, the classical pharmacologic treatment, as well as the active and passive immunization describing drug prototypes evaluated in different clinical trials.
阿尔茨海默病（AD）是成人起病的最常见痴呆形式，其特征为认知和记忆进行性受损。该疾病无法治愈，目前的治疗仅为对症治疗。药物研发是一个昂贵且耗时的过程；尽管科学界和制药公司付出了努力，但在过去十年中尚未发现用于AD的新药。β-淀粉样蛋白（Aβ）免疫疗法是改变AD病程最有前景的方法之一。这种治疗策略使用合成肽或单克隆抗体（mAb）来降低大脑中的Aβ负荷并减缓疾病进展。因此，本文将讨论AD神经发病机制的主要方面、经典药物治疗，以及描述在不同临床试验中评估的药物原型的主动和被动免疫。
